412 related articles for article (PubMed ID: 25307085)
1. Biosimilars lining up to compete with Herceptin--opportunity knocks.
Nelson KM; Gallagher PC
Expert Opin Ther Pat; 2014 Nov; 24(11):1149-53. PubMed ID: 25307085
[TBL] [Abstract][Full Text] [Related]
2. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
Thill M
Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
[TBL] [Abstract][Full Text] [Related]
3. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
Cesarec A; Likić R
Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
Liu T; Liu D; Jin Y; Dong M
Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
[TBL] [Abstract][Full Text] [Related]
5. [Trastuzumab (herceptin) for the medical treatment of breast cancer].
Bayoudh L; Afrit M; Daldoul O; Zarrad M; Boussen H
Tunis Med; 2012 Jan; 90(1):6-12. PubMed ID: 22311450
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of the trastuzumab biosimilar CT-P6.
Jeong SA; Choi JM; Park JM; Lee JY; Lee SJ; Lee SY; Lee SY; Park YA; Jeong HJ; Song YC; Kim SH; Chang SJ
Expert Opin Biol Ther; 2019 Oct; 19(10):1085-1095. PubMed ID: 30541352
[No Abstract] [Full Text] [Related]
7. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
[TBL] [Abstract][Full Text] [Related]
9. [Trastuzumab and its biosimilars].
Sarosiek T; Morawski P
Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
[TBL] [Abstract][Full Text] [Related]
11. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
Whalen J
Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.
Perez-Ellis C; Goncalves A; Jacquemier J; Marty M; Girre V; Roché H; Brain E; Moatti JP; Viens P; Le Corroller-Soriano AG
Am J Clin Oncol; 2009 Oct; 32(5):492-8. PubMed ID: 19487912
[TBL] [Abstract][Full Text] [Related]
13. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
14. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
Jackisch C; Lammers P; Jacobs I
Breast; 2017 Apr; 32():199-216. PubMed ID: 28236776
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
Morris SR; Carey LA
Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
[TBL] [Abstract][Full Text] [Related]
16. Controversies in the use of adjuvant trastuzumab (Herceptin).
Chowdhury S; Pickering L; Ellis P
J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
[TBL] [Abstract][Full Text] [Related]
17. The evolution of biosimilars in oncology, with a focus on trastuzumab.
Nixon NA; Hannouf MB; Verma S
Curr Oncol; 2018 Jun; 25(Suppl 1):S171-S179. PubMed ID: 29910660
[TBL] [Abstract][Full Text] [Related]
18. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer.
Muñoz C; Tai X; Arias J; Eisen A; Chaudhry M; Gavura S; Chan KKW
Curr Oncol; 2024 Mar; 31(3):1633-1644. PubMed ID: 38534957
[No Abstract] [Full Text] [Related]
20. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
Paplomata E; Nahta R
Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
